Navigation Links
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity

MOUNTAIN VIEW, Calif., Dec. 29 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation medical therapies to address unmet needs in obesity, diabetes and sexual health, announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of Qnexa, its investigational drug for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.

The NDA submission follows the successful completion of the phase 3 program for Qnexa, including the recently announced results from the two pivotal, year-long phase 3 studies, EQUIP and CONQUER. In these trials, patients treated with all three doses of Qnexa achieved significant percent and categorical weight loss compared to placebo and met regulatory requirements for weight loss products as defined in the current FDA Guidance for Developing Products for Weight Management. Patients treated with Qnexa also had significant dose-related improvements in a variety of secondary endpoints including reductions in cardiovascular and metabolic risk factors.

"This NDA filing is a major milestone for VIVUS and the Qnexa program. The weight loss seen in all of the phase 3 trials supports our belief that, if approved, Qnexa could be an effective treatment for patients who are obese or overweight with co-morbidities," stated Leland F. Wilson, chief executive officer for VIVUS. "The weight loss of up to 14.7% (37 pounds) combined with significant improvements in weight-related medical conditions, such as hypertension, diabetes, and dyslipidemia, demonstrates the importance of treating obesity, which has become a major epidemic in the United States and many developed countries. I wish to thank all of the VIVUS employees, contractors and advisors who contributed to the program and made this on-time filing possible."

Previously reported highlights from the two 56-week EQUIP and CONQUER studies comprising more than 3,750 patients include:

  • Weight loss of up to 14.7% (37 lbs) achieved by patients treated with Qnexa for 56 weeks in the EQUIP study;
  • Statistically significant improvements in cardiovascular, metabolic and inflammatory risk factors among patients treated with Qnexa;
  • FDA efficacy benchmarks for weight loss agents were exceeded at all three doses of Qnexa tested in the clinical program;
  • Completion rates up to 69% were statistically significantly higher than placebo at all three doses of Qnexa, indicating favorable tolerability; and
  • Across both 56-week studies, the most commonly reported side effects were dry mouth, tingling and constipation.

About the Phase 3 Program

The phase 3 clinical program, evaluating Qnexa in more than 4,500 patients, was designed under a Special Protocol Assessment with the U.S. FDA and consists of three trials: EQUATE (OB-301), EQUIP (OB-302) and CONQUER (OB-303). The EQUATE study was a 28-week randomized, double-blind, placebo-controlled, 7-arm, prospective trial with subjects randomized to receive once-a-day treatment with mid- or full-dose Qnexa, the respective constituents, or placebo. The average baseline BMI of the study population was 36.3 kg/m(2) with an average baseline weight of 223 pounds. The EQUIP and CONQUER studies were 56-week, randomized, double-blind, placebo-controlled, 3-arm, prospective trials with patients randomized to receive once-a-day treatment with low-, mid-, or full-dose Qnexa, or placebo. In EQUIP, the average baseline BMI of the study population was 42.1 kg/m(2) with an average baseline weight of 256 pounds; in CONQUER, the average baseline BMI of the study population was 36.6 kg/m(2) with an average baseline weight of 227 pounds. All patients were asked to follow a hypocaloric diet representing a 500-calorie/day deficit and advised to implement a simple lifestyle modification program.

About Qnexa

Qnexa (Q-NEX-uh) is an investigational drug being developed to address weight loss. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate, which is believed to address both appetite and satiety - the two main mechanisms that impact eating behavior - in one capsule. In phase 2 and 3 clinical studies, Qnexa has demonstrated significant weight loss, glycemic control, and improvement in cardiovascular risk factors.


VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa, has recently completed phase 3 clinical trials for the treatment of obesity and an NDA was submitted to the FDA in December 2009. Qnexa is currently in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2008 and periodic reports filed with the Securities and Exchange Commission.


    VIVUS, Inc.              Investor Relations:  The Trout Group
    Timothy E. Morris                             Brian Korb
    Chief Financial Officer                       646-378-2923

                             Media Relations:     Pure Communications, Inc.
                                                  Dan Budwick


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Eli Lilly and Company ... square feet and approximately 50 new jobs to its research ... New York, New York . ... 2016, this space will include a translational immuno-oncology hub and ... opportunities for collaborative access to cutting-edge drug discovery capabilities, including ...
(Date:10/9/2015)... 9, 2015 Ansun BioPharma announced a presentation ... America ) regarding the compassionate use of DAS181 under ... respirator who was co-infected with influenza and parainfluenza (Abstract ... therapy, O 2 requirement was reduced and the ... to go off the respirator on day 5. Between ...
(Date:10/9/2015)... , Suiza, October 9, 2015 El ,JCA-Mauvernay ... Yutaka Kondo y Junko Takita    ... otorgado a los doctores Yutaka Kondo y ... ,JCA-Mauvernay Award 2015, se ha otorgado a los doctores ...    ™ , una compañía biofarmacéutica global con sede enSuiza, ...
Breaking Medicine Technology:
... NEW YORK, Sept. 12, 2011 A revolutionary new ... other technology - - the VivoSight® Optical Coherence ... to dermatologists in the U.S. for the first time. ... skin surface instantly, providing additional information which will allow ...
... Sept. 12, 2011 Intarcia Therapeutics, Inc. announced ... ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) ... the 47th Annual Meeting of the European Association ...  All three presentations are scheduled for Wednesday, September ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... Doctors on Liens has teamed up with ... highly needed medical care to personal injury victims. When personal injury victims suffer ... and treat the variety of conditions ailing them. With the addition of this ...
(Date:10/9/2015)... ... October 09, 2015 , ... For many, October is a month whose focus ... effort to find a cure. At Beverly Hills Physicians in Southern California, it is ... their Bra Collection Campaign, Beverly Hills Physicians is encouraging patients and non-patients alike to ...
(Date:10/9/2015)... ... October 09, 2015 , ... "My spouse and I rely on ... leaned against something," said an inventor from Buffalo, N.Y. "This is not only frustrating ... , The CANE REST enables a user to keep a cane upright while it’s ...
(Date:10/9/2015)... Beach, CA (PRWEB) , ... October 09, 2015 ... ... is now offering a special promotion on Invisalign, the orthodontic system that uses ... reasons. The aligners are almost invisible against the teeth, which allow patients to ...
(Date:10/9/2015)... ... ... On Saturday, September 26, 2015, 48-year-old MS survivor and entrepreneur Lucie B won ... USA and Sweden in the Speed and Power events, which consisted of 30-Second Single ... 1 Silver and 4 Gold Medals. , “I remember looking at my competitors and ...
Breaking Medicine News(10 mins):
... Understanding the structure of proteins involved in inhibiting ... and University of Minnesota researchers have taken a crucial ... Harris, Ph.D., co-investigators of the research and assistant professors ... at the University of Minnesota have determined the structure ...
... arteries upped chances of cardiovascular trouble, study finds ... to detecting breast cancer in its early stages, new ... women are at risk for strokes. , Calcifications found ... doctors call benign arterial calcifications -- were more commonly ...
... to Veterans, BILLINGS, Mont., Feb. 20 Secretary ... creation of a,special "Rural Health National Advisory Committee" to ... Veterans Affairs (VA) about health care,issues affecting veterans in ... created outpatient clinics that bring,health care closer to where ...
... HUNTINGTON BEACH, Calif., Feb. 20 Barry,Arbuckle, Ph.D. has ... Board of Trustees. Dr. Arbuckle is president and CEO ... hospitals in,Los Angeles and Orange counties and headquartered in ... ), "I am honored to serve as ...
... by Pinot Noir has never been so irresistible!, SAN ... you to experience supple, sexy, velvety, and unforgettable wines as,you ... Shootout in a,blind tasting at The Golden Gate Room, Fort ... expert panel. Each guest will taste the wines,and cast their ...
... 20 The following is a,statement from Jeff ... (TFAH) in response to today,s release of Public ... Report on the Public Health Emergency,Preparedness Cooperative Agreement:, ... states have made to,improve public health emergency preparedness ...
Cached Medicine News:
... Built on the market leading optical performance ... has been optimized for even better views ... system, including a new XHL Xenon Halogen ... cornea and clear, high resolution images of ...
... 2.2 Fr Sur-Catch NT stone retrieval basket raises ... Its unique paired wire design and multi-sizing ... the needs of each patient and procedure. ... for use with the DURTM-8 Elite Ureteroscope and ...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
... is a minimally invasive, highly effective surgical ... incontinence. GYNECARE TVT is positioned close to ... and when needed, TVT provides tension-free support ... The procedure takes approximately 20 to 30 ...
Medicine Products: